Therefore, we hypothesize that combining PDIA3 inhibitors with tyrosine kinase inhibitors (such as Neratinib, Trastuzumab, and Pertuzumab) could enhance the inhibitory effect of tyrosine kinase inhibitors on breast cancer cells. Here, PDIA3 is linked to breast carcinoma.